Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company specializes in therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein commonly found in various tumors but absent in normal tissues, making it a promising target for cancer treatment. Its lead product, VLS-101, is designed as a ROR1-directed ADC aimed at patients with both hematologic and solid tumor malignancies. Founded in 2017, VelosBio has demonstrated positive preclinical results for its ROR1-directed therapeutics, paving the way for potential use in monotherapy or in combination with other treatments across a wide range of cancers. As of late 2020, VelosBio operates as a subsidiary of Merck & Co., Inc.
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.
Immix Biopharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer patients, particularly those resistant to traditional treatments. The company's product pipeline includes Imx-109, a small molecule designed to enhance the effectiveness of checkpoint therapies and other treatment modalities; Imx-110, a nanoparticle delivery system that combines cytotoxins with synergistic agents; and Imx-111, a targeted variant of Imx-110. Additionally, Immix Biopharma is advancing Imx-004, a humanized antibody targeting specific tumor markers. The company employs its proprietary TME Normalization Technology to improve drug delivery to tumors while minimizing side effects. Founded in 2014 and based in Los Angeles, California, Immix Biopharma is dedicated to addressing the needs of patients with hematologic malignancies and other cancer types through its advanced therapeutic candidates.
MatriSys Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing microbiome therapies specifically for dermatology and skin care. Headquartered in La Jolla, California, the company offers its lead product, MSB-01, a topical antimicrobial live bio therapeutic aimed at treating atopic dermatitis by restoring the necessary skin bacteria for effective host defense. In addition to therapeutics, MatriSys develops cosmetic ingredients derived from proprietary bacterial strains to address various skin conditions, including scaling, redness, and signs of aging. The company is exploring commercialization avenues across dermatology, skin care, and cosmetic sectors, with its lead therapeutic currently undergoing Phase I/II clinical trials. MatriSys aims to enhance skin health by rebalancing the skin's microbiome, promoting beneficial microbes while targeting harmful species.
NeuraLace Medical, Inc., founded in 2016 and headquartered in San Diego, California, focuses on developing a hardware-based neuromodulation platform aimed at the management of neuropathic pain. The company is creating a non-invasive interface that selectively stimulates sensory nerve fibers, providing a potential solution for chronic pain relief. By bridging the gap between technology and neurology, NeuraLace Medical aims to deliver effective pain management solutions on a broader scale.
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.
Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.
Alastin Skincare, based in Carlsbad, California, specializes in the development and marketing of innovative skincare products aimed at correcting, protecting, and maintaining healthy skin. Founded in 2015, the company offers a range of clinically validated products, including restorative treatments for the eye, skin, and neck, as well as body treatments and a variety of cleansers, sunscreens, and moisturizers. Central to their formulations is TriHex Technology, which utilizes a proprietary blend of peptides and other active ingredients to enhance the skin’s natural regenerative properties. Alastin's products are designed for use by dermatologists and plastic surgeons, supporting both ablative and non-ablative rejuvenating procedures. The company markets its products primarily through online channels.
Biscayne Pharmaceuticals, Inc. is a biopharmaceutical company based in Miami, Florida, focused on developing therapies that leverage growth hormone-releasing hormone (GHRH) analogs. The company is engaged in creating GHRH antagonists aimed at treating various cancers, including castrate-resistant prostate cancer, and GHRH agonists intended for cardiac repair in patients with heart disease. Additionally, Biscayne Pharmaceuticals is involved in developing drugs for refractory epilepsy and drug-resistant cancer by targeting GHRH receptors, which play a critical role in stimulating growth hormone production for tissue growth and repair. Since its incorporation in 2012, the company has aimed to provide innovative treatments for patients with challenging medical conditions.
Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel therapies for difficult-to-treat neurological disorders. Biscayne’s lead compound, BIS-001, is in clinical development for the treatment of refractory forms of epilepsy. Biscayne Neurotherapeutics has an experienced executive team with an extensive track record of successful drug development, and its scientific advisors include a number of highly respected experts studying seizure and other CNS disorders. The company is headquartered in Miami, Florida, and benefits from the growing entrepreneurial South Florida biomedical sector.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Their pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies. Oncternal Therapeutics cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. They also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).
Independa, Inc. specializes in developing cloud-based wellness and social engagement software solutions tailored for senior citizens. The company's offerings include the AnyTV Companion, a remote care platform that facilitates social engagement and provides essential reminders for medications and appointments, as well as CloudCare, an enterprise solution that encompasses various modules for remote care, wellness, and community involvement. Independa also offers a caregiver dashboard that enables both professional and personal caregivers to monitor the needs of care recipients effectively. Additionally, its solutions feature smart reminders, broadcast messaging for alerts and notifications, and integrated monitoring that connects health devices and home sensors to ensure the safety and well-being of seniors. Founded in 2009 and headquartered in San Diego, California, Independa serves a diverse clientele, including senior living communities, rehabilitation centers, hospitals, insurance companies, and home care organizations. The company has established a strategic partnership with LG Electronics to enhance its service offerings.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.
Biomatrica (www.biomatrica.com) is a San Diego-based biostability company that provides innovative technologies for stabilizing, processing, storing and shipping biological samples at room temperature. The core technology is designed for use in preserving complex biological samples and assays and is based on the principles of anhydrobiosis (“life without waterâ€), a natural mechanism that allows multicellular organisms to survive extreme environments. Biomatrica's current products stabilize DNA, RNA, proteins, cells and assays with no sample degradation, allowing scientists and clinicians to have pristine samples and reduce their reliance on freezers and drastically reduce shipping costs. Biomatrica products are used in laboratories performing life science research, from pharmaceutical and biotechnology companies to academic research and forensics laboratories. Custom services to stabilize additional sample types are also available. Biomatrica also offers SampleWare® software, an easy-to-use, customizable laboratory management database that provides scientists with the means to store and organize their sample data, and directly supports samples stabilized by Biomatrica technology. For more information about the SampleMatrix technology and the Biomatrica products utilizing this technology platform (DNAstable®, DNAstable Blood, DNAgard Tissue and DNAgard Blood for DNA, RNAstable® and RNAconcentrator for RNA, and CloneStable® for bacterial DNA),
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.
Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.
Medipacs, Inc. is a company specializing in the development of non-mechanical infusion pumps designed to administer a variety of medications, including biologic drugs, insulin, hormones, fertility treatments, anti-coagulation agents, and pain relief medications. Founded in 2004, Medipacs is headquartered in San Diego, California, and operates research facilities in Tucson, Arizona. The company's innovative approach aims to enhance the delivery of essential therapies in a more efficient and effective manner.